fashion -WSS

fashion

author：focus 2025-09-30 17:59:29 - browse：97291

Adam's take main illustration — Molly Ferguson/STAT

Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not close. Six months from now, or sooner, Novartis will walk away — slightly embarrassed but otherwise unscathed — happy to pay a small breakup fee to MorphoSys to avoid owning a drug for myelofibrosis that regulators turned away.

MorphoSys will not fare as well from the breakup. Its future, and that of the drug called pelabresib at the center of the deal, will be thrown into limbo.

This is all speculation on my part, but it’s supported by separate conversations with two people familiar with pelabresib and the debate inside Novartis over the MorphoSys acquisition. They requested anonymity to discuss confidential matters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： ‘The Bear’ and hospitality in hospitals

WSS

Lessons Learned: This is why you network to find that industry job you want

Hospitals use virtual reality to design more inclusive rooms for kids

‘The Bear’ and hospitality in hospitals

Weighted lottery helped low

House transparency, PBM reform bill gains bipartisan support

Germany receives 178 compensation applications from gay servicepeople over discrimination

leisure time

fashion

Wikipedia

Duchenne breakthrough therapy leaves behind pioneering families

What drug price negotiations mean for Medicare Part D

Peter Hotez and the public health issue of online harassment

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

ChatGPT in medicine: STAT answers readers' burning questions

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

Apple is now the first public company to be valued at $3 trillion

NIH nominee Bertagnolli will get October confirmation hearing

George Santos makes 1st court appearance after pleading not guilty to 13 counts

AstraZeneca chief proposes a novel edit to the drug pricing bill

explore

Astronauts get first look at the spacecraft that will fly them around the moon

Covid hospitalizations on the rise, Humana says

CDC launches VaccineFinder tool to locate Covid

Amazon on where the company's health care bets are headed next

Advances in CAR

A rare thyroid diagnosis led to unexpected, all

focus

explore

knowledge

leisure time